©2024 Stanford Medicine
Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia
Not Recruiting
Trial ID: NCT00537030
Purpose
This clinical trial is studying the side effects of Erwinia asparaginase and what happens to
the drug in the body in treating young patients with acute lymphoblastic leukemia who are
allergic to PEG-asparaginase. Drugs used in chemotherapy, such as Erwinia asparaginase, work
in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing.
Official Title
Pharmacology and Toxicity of Erwinia Asparaginase (Erwinase?; Crisantaspase; IND 290) Following Allergy to PEG-Asparaginase in Treatment of Children With Acute Lymphoblastic Leukemia (ALL)
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Diagnosis of acute lymphoblastic leukemia
- Concurrently enrolled on a frontline Children's Oncology Group treatment trial (i.e.,
COG-AALL0232 or COG-AALL0531, COG-AALL0331, or COG-AALL0434) at a participating
institution
- Must have 1 or more courses of asparaginase remaining to be administered on the
treatment protocol
- Must have had a grade ? 2 hypersensitivity reaction to PEG-asparaginase
- No history of pancreatitis ? grade 2
- No prior Erwinia asparaginase
Intervention(s):
other: laboratory biomarker analysis
other: pharmacological study
drug: asparaginase
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Peds Hem/Onc CRAs
650-723-5535